Gout flares are commonly treated with colchicine, which can provoke GI side effects, particularly diarrhea. The Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial investigated the efficacy ...

The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

An exploratory analysis of the LoDoCo2 (Low-Dose Colchicine 2) randomized, controlled, double-blind trial found that daily therapy with a low dose of colchicine was associated with lower incidences of ...

Jan Cornel and C. Michael Gibson Discuss: LoDoCo2 Low-Dose Colchicine in Coronary Disease. Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is ...

Please provide your email address to receive an email when new articles are posted on . In patients with chronic coronary disease, adding low-dose colchicine to optimal medical therapy reduced risk ...

May 7, 2010 — The US Food and Drug Administration (FDA) has issued new dosing guidelines for colchicine (Colcrys tablets; URL Pharma, Inc) when used with protease inhibitors in HIV patients. According ...

Please provide your email address to receive an email when new articles are posted on . Benefits of low-dose colchicine were consistent in men over a median follow-up period of 28.6 months. Due to low ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of ...

IMPROVEMENT from colchicine therapy in patients with arthritic symptoms has always been accepted as indicative of gout. 1–3 Other arthritides supposedly have not responded satisfactorily to this ...